Scil Proteins establishes business development organisation in California

To be headed by Garry Merry

Scil Proteins, a German biotech specialist in the research, development and production of recombinant proteins, has established a business development organisation in California in response to increasing demand for the company’s protein production services in North America. The organisation, to be led by Garry Merry, will provide local business support for the company’s US and Canadian CMO customers.

Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies, Isogenica and TerraSep. He has also held senior executive positions at life science companies including Waters, Applied Biosystems and Qiagen.

‘A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,’ said Frank Ubags, chief operating officer of Scil Proteins. ‘With his background in protein engineering and separations, Garry is ideally positioned to help us achieve our growth objectives.’

Scil Proteins’ Affilin drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the company’s headquarters in Halle, Germany. The corporate headquarters will also remain responsible for all other activities related to the company’s CMO business outside the US and Canada.

You may also like